Chemomab Therapeutics Reports Q1 2025 Results
Ticker: CMMB · Form: 6-K · Filed: May 15, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, corporate-update, biotech
Related Tickers: CMMB
TL;DR
Chemomab Therapeutics (CMMB) dropped its Q1 2025 earnings report on 5/15/25. Check it out.
AI Summary
Chemomab Therapeutics Ltd. announced its first quarter 2025 financial results and provided a corporate update on May 15, 2025. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is focused on the pharmaceutical preparations industry. The filing is a Form 6-K report.
Why It Matters
This filing provides investors with the latest financial performance and operational updates from Chemomab Therapeutics, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Chemomab Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Registrant
- Anchiano Therapeutics Ltd. (company) — Former company name
- BioCancell Ltd. (company) — Former company name
- May 15, 2025 (date) — Date of press release and filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the issuance of a press release by Chemomab Therapeutics Ltd. on May 15, 2025, titled 'Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update'.
What were Chemomab Therapeutics' former names?
Chemomab Therapeutics Ltd. was formerly known as Anchiano Therapeutics Ltd. (name change effective September 6, 2018) and BioCancell Ltd. (name change effective November 4, 2011).
What is Chemomab Therapeutics' Standard Industrial Classification (SIC) code?
Chemomab Therapeutics Ltd.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Chemomab Therapeutics Ltd. headquartered?
Chemomab Therapeutics Ltd. is headquartered in Tel Aviv, Israel, with its principal executive offices located at Kiryat Atidim, Building 7.
Which form does Chemomab Therapeutics file its annual reports under?
Chemomab Therapeutics files its annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 15, 2025 regarding Chemomab Therapeutics Ltd. (CMMB).